Frequency of Fecal Calprotectin Testing in Inflammatory Bowel Disease

Monitoring Recommendations Based on Clinical Status

The American Gastroenterological Association recommends that fecal calprotectin should be repeated every 6-12 months in patients with inflammatory bowel disease (IBD) who are in symptomatic remission, and every 2-4 months in patients being treated for active symptoms 1, 2
Interval biomarker monitoring should be performed every 6-12 months in patients in symptomatic remission, as recommended by the American Gastroenterological Association 1
Biomarker-based monitoring is particularly useful in patients whose biomarkers have historically correlated with endoscopic disease activity, according to the American Gastroenterological Association 1
In patients with elevated biomarkers but sustained symptomatic remission, repeat measurement of biomarkers in 3-6 months may be a reasonable alternative to endoscopic assessment, as suggested by the American Gastroenterological Association 1, 3
If biomarkers remain elevated on repeat evaluation, then endoscopic assessment is warranted, according to the American Gastroenterological Association 3

Fecal calprotectin <150 μg/g suggests minimal inflammation and can rule out active inflammation in patients in symptomatic remission, as indicated by the American Gastroenterological Association 4, 3
Fecal calprotectin >150 μg/g suggests possible active inflammation and may warrant further evaluation, according to the American Gastroenterological Association 4, 3
In patients who have recently achieved symptomatic remission after treatment adjustment in the preceding 1-3 months, a lower cutoff of <50 μg/g may be preferred to detect endoscopic improvement, as recommended by the American Gastroenterological Association 3, 5

In patients with elevated calprotectin but no symptoms, repeat testing in 3-6 months is reasonable before proceeding to endoscopy, according to the American Gastroenterological Association 3, 5
Lack of normalization or persistently elevated biomarkers in patients whose symptoms recently resolved after initial treatment likely suggests active inflammation and may warrant treatment adjustment without need for endoscopic evaluation, as suggested by the American Gastroenterological Association 1
For patients with predominantly small bowel Crohn's disease, radiologic assessment may be a reasonable alternative to endoscopic assessment, as recommended by the American Gastroenterological Association 2